OBJECTIVE: S100A4 is a DAMP protein. S100A4 is overexpressed in patients with systemic sclerosis (SSc), and levels correlate with organ involvement and disease activity. S100A4-/- mice are protected from fibrosis. The aim of this study was to assess the antifibrotic effects of anti-S100A4 monoclonal antibody (mAb) in murine models of SSc and in precision cut skin slices of patients with SSc. METHODS: The effects of anti-S100A4 mAbs were evaluated in a bleomycin-induced skin fibrosis model and in Tsk-1 mice with a therapeutic dosing regimen. In addition, the effects of anti-S100A4 mAbs on precision cut SSc skin slices were analyzed by RNA sequencing. RESULTS: Inhibition of S100A4 was effective in the treatment of pre-established bleomycin-induced skin fibrosis and in regression of pre-established fibrosis with reduced dermal thickening, myofibroblast counts, and collagen accumulation. Transcriptional profiling demonstrated targeting of multiple profibrotic and proinflammatory processes relevant to the pathogenesis of SSc on targeted S100A4 inhibition in a bleomycin-induced skin fibrosis model. Moreover, targeted S100A4 inhibition also modulated inflammation- and fibrosis-relevant gene sets in precision cut SSc skin slices in an ex vivo trial approach. Selected downstream targets of S100A4, such as AMP-activated protein kinase, calsequestrin-1, and phosphorylated STAT3, were validated on the protein level, and STAT3 inhibition was shown to prevent the profibrotic effects of S100A4 on fibroblasts in human skin. CONCLUSION: Inhibition of S100A4 confers dual targeting of inflammatory and fibrotic pathways in complementary mouse models of fibrosis and in SSc skin. These effects support the further development of anti-S100A4 mAbs as disease-modifying targeted therapies for SSc.

Agiana Pharmaceuticals Oslo Norway

Arxx Therapeutics Oslo Norway

Arxx Therapeutics Oslo Norway and Roskilde University Roskilde Denmark

Charles University Prague Czech Republic

Friedrich Alexander University of Erlangen Nürnberg Erlangen Germany

Helios St Elisabeth Klinik Oberhausen University Witten Herdecke Oberhausen and Helios St Johannes Klinik Duisburg Duisburg Germany

Helios St Elisabeth Klinik Oberhausen University Witten Herdecke Oberhausen Germany

University Hospital Düsseldorf and Heinrich Heine University Düsseldorf Germany

See more in PubMed

Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390(10103):1685–1699.

Distler JHW, Györfi AH, Ramanujam M, et al. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 2019;15(12):705–730.

Distler JH, Schett G, Gay S, et al. The controversial role of tumor necrosis factor α in fibrotic diseases. Arthritis Rheum 2008;58(8):2228–2235.

Bhattacharyya S, Wang W, Qin W, et al. TLR4‐dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight 2018;3(13):e98850.

Bhattacharyya S, Kelley K, Melichian DS, et al. Toll‐like receptor 4 signaling augments transforming growth factor‐β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 2013;182(1):192–205.

Fei F, Qu J, Li C, et al. Role of metastasis‐induced protein S100A4 in human non‐tumor pathophysiologies. Cell Biosci. 2017;7:64.

Ambartsumian N, Klingelhöfer J, Grigorian M. The multifaceted S100A4 protein in xancer and inflammation. Methods Mol Biol 2019;1929:339–365.

Tomcik M, Palumbo‐Zerr K, Zerr P, et al. S100A4 amplifies TGF‐β‐induced fibroblast activation in systemic sclerosis. Ann Rheum Dis 2015;74(9):1748–1755.

Tomcik M, Andres Cerezo L, Skacelova S, et al. Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis [abstract]. Ann Rheum Dis 2014;73(suppl 1):A48.

Cerezo LA, Remakova M, Tomcik M, et al. The metastasis‐associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2014;53(8):1520–1526.

Neidhart M, Pajak A, Laskari K, et al. Oligomeric S100A4 is associated with monocyte innate immune memory and sypass of tolerance to subsequent stimulation with lipopolysaccharides. Front Immunol 2019;10:791.

Grum‐Schwensen B, Klingelhöfer J, Beck M, et al. S100A4‐neutralizing antibody suppresses spontaneous tumor progression, pre‐metastatic niche formation and alters T‐cell polarization balance. BMC Cancer 2015;15:44.

Bruhn S, Fang Y, Barrenas F, et al. A generally applicable translational strategy identifies S100A4 as a candidate gene in allergy. Sci Transl Med 2014;6(218):218ra4.

Zhang J, Hou S, Gu J, et al. S100A4 promotes colon inflammation and colitis‐associated colon tumorigenesis. Oncoimmunology 2018;7(8):e1461301.

Chen L, Li J, Zhang J, et al. S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J Hepatol 2015;62(1):156–164.

Klingelhöfer J, Grum‐Schwensen B, Beck MK, et al. Anti‐S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012;14(12):1260–1268.

Bhattacharyya S, Wang W, Morales‐Nebreda L, et al. Tenascin‐C drives persistence of organ fibrosis. Nat Commun 2016;7:11703.

Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63(5):1396–1404.

Li YN, Chen CW, Trinh‐Minh T, et al. Dynamic changes in O‐GlcNAcylation regulate osteoclast differentiation and bone loss via nucleoporin 153. Bone Res 2022;10(1):51.

Masi, AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23(5):581–590. Portico. https://doi.org/10.1002/art.1780230510

van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemicsclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72(11):1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424

Cheng D, Xu Q, Wang Y, et al. Metformin attenuates silica‐induced pulmonary fibrosis via AMPK signaling. J Transl Med 2021;19(1):349.

Yang W, Wang L, Wang F, et al. Roles of AMP‐activated protein kinase (AMPK) in mammalian reproduction. Front Cell Dev Biol 2020;8:593005.

Protasi F, Paolini C, Dainese M. Calsequestrin‐1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke. J Physiol 2009;587(pt 13):3095–3100.

Zhou X, Trinh‐Minh T, Tran‐Manh C, et al. Impaired mitochondrial transcription factor a expression promotes mitochondrial damage to drive fibroblast activation and fibrosis in systemic sclerosis. Arthritis Rheumatol 2022;74(5):871–881.

Dees C, Potter S, Zhang Y, et al. TGF‐β‐induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Invest 2020;130(5):2347–2363.

Zehender A, Huang J, Györfi AH, et al. The tyrosine phosphatase SHP2 controls TGFβ‐induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nat Commun 2018;9(1):3259.

Chakraborty D, Šumová B, Mallano T, et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 2017;8(1):1130.

Zhang Y, Liang R, Chen CW, et al. JAK1‐dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long‐term treatment. Ann Rheum Dis 2017;76(8):1467–1475.

Zhang Y, Dees C, Beyer C, et al. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis. Ann Rheum Dis 2015;74(5):936–943.

Dees C, Tomcik M, Palumbo‐Zerr K, et al. JAK‐2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum 2012;64(9):3006–3015.

Li Z, Li Y, Liu S, et al. Extracellular S100A4 as a key player in fibrotic diseases. J Cell Mol Med 2020;24(11):5973–5983.

Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010;62(10):2831–2844.

Clark KEN, Csomor E, Campochiaro C, et al. Integrated analysis of dermal blister fluid proteomics and genome‐wide skin gene expression in systemic sclerosis: an observational study. Lancet Rheumatol 2022;4(7):e507–e516.

Jaeger VK, Lebrecht D, Nicholson AG, et al. Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease‐related lung fibrosis. Sci Rep 2019;9(1):5500.

Tsitoura E, Vasarmidi E, Bibaki E, et al. Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. Respir Res 2019;20(1):264.

Ganaie AA, Mansini AP, Hussain T, et al. Anti‐S100A4 antibody therapy is efficient in treating aggressive prostate cancer and reversing immunosuppression: serum and biopsy S100A4 as clinical predictor. Mol Cancer Ther 2020;19(12):2598–2611.

Sakic A, Chaabane C, Ambartsumian N, et al. Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells. Cardiovasc Res 2022;118(1):141–155.

Zibert JR, Skov L, Thyssen JP, et al. Significance of the S100A4 protein in psoriasis. J Invest Dermatol 2010;130(1):150–160.

Li Y, Bao J, Bian Y, et al. S100A4+ macrophages are necessary for pulmonary fibrosis by activating lung fibroblasts. Front Immunol 2018;9:1776.

Nakatani K, Asai O, Konishi N, et al. Role of fibroblast specific protein 1 expression in the progression of adriamycin‐induced glomerulosclerosis. Biochem Biophys Res Commun 2021;567:148–153.

Liu S, Liu M, Zhong J, et al. Anti‐S100A4 antibody administration alleviates bronchial epithelial‐mesenchymal transition in asthmatic mice. Open Med (Wars) 2023;18(1):20220622